| Literature DB >> 34690144 |
Neal R Swerdlow1, Juliana E Kotz1, Yash B Joshi1,2, Jo Talledo1, Joyce Sprock1,2, Juan L Molina1,2, Branko Huisa3, Steven F Huege1, Jairo Alberto Romero4, Michael J Walsh1, Lisa Delano-Wood1, Gregory A Light1,2.
Abstract
Memantine's benefits in Alzheimer's disease (AD) are modest and heterogeneous. We tested the feasibility of using sensitivity to acute memantine challenge to predict an individual's clinical response. Eight participants completed a double-blind challenge study of memantine (placebo versus 20 mg) effects on autonomic, subjective, cognitive, and neurophysiological measures, followed by a 24-week unblinded active-dose therapeutic trial (10 mg bid). Study participation was well tolerated. Subgroups based on memantine sensitivity on specific laboratory measures differed in their clinical response to memantine, some by large effect sizes. It appears feasible to use biomarkers to predict clinical sensitivity to memantine.Entities:
Keywords: Alzheimer’s disease; event-related potentials; memantine; neurocognition; prepulse inhibition
Mesh：
Substances：
Year: 2021 PMID： 34690144 PMCID： PMC8881988 DOI： 10.3233/JAD-215029
Source DB: PubMed Journal: J Alzheimers Dis ISSN： 1387-2877 Impact factor: 4.472